Home
About Us
Strategy
News
Careers Contact Us
CN EN
CN | EN
ABOUT US
Introduction Milestones Management Team Advisory Board of Clinical Experts Vision & Mission
2017
2018
2019
2020
2021
2022
2023
2024
2017
Dec, BioCity founded
2018
Early drug discovery
2019
Early drug discovery
Dec, First IND approval by the NMPA（ No. BC3425）
2020
Completed series A financing
Jun, Second IND approval by the NMPA ( No.SC0062)
Sep, Third IND approval by the NMPA (No.BC3402)
Oct, Fourth IND approval by the NMPA (No.SC0245)
Nov, Fifth IND approval by the NMPA (No.SC0191)
2021
Oct, Wuxi Translational Medicine Center in operation
Nov, Strategic framework agreement signed with AstraZeneca
Nov, Initiated the construction of the first phase I clinical trial base
2022
Jan, First patient Dosing in CD3/EGFR BsAb BC3448 Phase Ⅰ trial
Jul, the second indication (SCLC) of SC0245 approval by NMPA
Dec，the Phase 2 trial application (IgA & DKD）of SC0062 approved by NMPA
Dec, The third indication（ Ovarian Cancer ）of SC0191 approval by NMPA
Shanghai R&D Center and Lab in operation
2023
Feb, Phase 1 trial application of FIC ADC（CDH3） BC3195 approval by FDA
Feb, Phase 1/2 trial of SC0191 approval by FDA
Feb, Phase 1 trial application of FIC ADC（CDH3） BC3195 approval by NMPA
June,the first patient dosed with SC0062 in Phase II trial in China
July,the first patient dosed with BC3195 in Phase I trial in China
Sep, Agreement with AstraZeneca on BC3402 in Combination with IMFINZI for the Treatment of HCC in China
Dec,the first patient dosed with BC3402 in Combination with IMFINZI for the Treatment of HCC in a Phase Ib/II Trial
U.S. Division Launches Operations
2024
Feb，Enrollment Completion of the IgAN Cohort in Phase II Clinical Trial of SC0062
April，FDA Clearance of the IND Application for BC2027 (a FIC GPC3 ADC)
June，Enrollment Completion of the DKD Cohort in Phase II Clinical Trial of SC0062
July，SC0062 met the primary endpoint in IgA nephropathy in 2-SUCCEED trial